Novo Nordisk A/S
CorpDigest
Novo Nordisk A/S
Financial Performance
Last reviewed: June 2026 · By Swet Parvadiya
Revenue
$42.7B
Market Cap
$550.0B
Net Income
$14.3B
Employees
77,900
Revenue grew from $24.8 billion in FY2022 to $33.4 billion in FY2023 to $42.7 billion in FY2024 — a two-year compound growth rate of approximately 31% that is, for a company of this size, essentially without precedent in pharmaceutical history. Operating profit reached 125.3 billion DKK in FY2024, with an operating margin of 43.1%. Free cash flow of 91.2 billion DKK was deployed partially into the record 28.6 billion DKK capital expenditure program to expand manufacturing capacity. The semaglutide franchise breakdown illustrates the market's composition: Ozempic (diabetes indication) generated 146.9 billion DKK, Wegovy (obesity indication) generated 68.2 billion DKK. The obesity market is structurally larger than the diabetes market in terms of addressable population, and Wegovy's growth rate in FY2024 significantly exceeded Ozempic's — suggesting that the revenue mix will continue shifting toward obesity over the medium term as manufacturing constraints ease and insurance coverage expands. The capital expenditure program of 28.6 billion DKK in FY2024 — the largest in European pharmaceutical history — reflects the magnitude of the capacity constraint. Novo Nordisk's active pharmaceutical ingredient production and sterile fill-finish capabilities cannot scale quickly; the regulatory requirements for pharmaceutical manufacturing mean that new capacity requires years of construction and validation before it can produce commercial product. Novo Holdings' acquisition of Catalent was intended to accelerate that timeline by acquiring existing validated facilities rather than building from scratch. The $550 billion market capitalization at fiscal year-end made Novo Nordisk the most valuable company in Europe by a significant margin, representing approximately 12.9x FY2024 revenue. That multiple prices in continued semaglutide dominance, successful next-generation product launches, and the expansion of GLP-1 indications beyond diabetes and obesity into cardiovascular disease, chronic kidney disease, and potentially other metabolic conditions.
Revenue Trend Analysis
YoY Change
+27.8%
2-Year CAGR
+31.2%
Peak Year
2024
Trend
Consistent Growth
Novo Nordisk A/S has reported revenue across 3 fiscal years, compounding at +31.2% annually over 2 years. The most recent year saw a 27.8% increase versus the prior year. Revenue peaked in 2024 at $42.7B. Out of 2 reported periods, 2 showed growth and 0 showed a decline.
| Fiscal Year | Revenue | Net Income | YoY Change |
|---|---|---|---|
| FY2024 | $42.7B | $14.3B | +27.8% |
| FY2023 | $33.4B | — | +34.7% |
| FY2022 | $24.8B | — | — |
Source: SEC EDGAR filings, annual earnings releases, and verified financial disclosures.
Click any row to see year details.
Novo Nordisk's revenue grew from DKK 122 billion in 2019 (approximately $18 billion) to DKK 290 billion in 2024 (approximately $42 billion), a roughly 2.4x increase across five years driven almost entirely by semaglutide. Annual revenue progression in DKK: 122 billion (2019), 127 billion (2020), 141 billion (2021), 177 billion (2022), 232 billion (2023), and 290 billion (2024). Growth rates accelerated from low-single-digit percentages in 2019-2020 to 24% in 2022, 31% in 2023, and 25% in 2024 — far outpacing the broader pharma industry's 5-7% annual revenue growth. The acceleration was driven by three product launches plus indication expansion. Ozempic (launched 2018) grew from approximately $1 billion in 2019 to $17.4 billion in 2024. Wegovy (launched 2021) grew from $0.2 billion in 2021 to $8.4 billion in 2024. Rybelsus (launched 2019) grew from $0 to $3.6 billion in 2024. The combined semaglutide franchise reached $29 billion in 2024, making it the single largest pharmaceutical franchise globally. Operating income grew commensurately from DKK 49 billion in 2019 to DKK 137 billion in 2024, with operating margin expanding from 40% to 47%. Net income reached DKK 100.5 billion in 2024, and earnings per share crossed DKK 22, supporting continued dividend growth and share-repurchase programs.
Novo Nordisk operated at a 47% operating margin in 2024 — one of the highest among large-cap global pharma companies. By comparison, Eli Lilly's 2024 operating margin was approximately 32% (depressed by tirzepatide manufacturing ramp), Pfizer near 18%, Merck near 24%, Bristol-Myers Squibb near 21%, AbbVie near 31%, Roche near 28%, and Novartis near 34% (post-Sandoz spin-off). Novo Nordisk's margin advantage reflects three structural drivers. First, product concentration: semaglutide alone generates over 70% of revenue at premium pricing and high gross margin, avoiding the overhead drag of maintaining diversified portfolios across many small franchises. Second, focused R&D: Novo Nordisk's R&D spending of approximately DKK 38 billion (roughly $5.5 billion, ~13% of revenue) is below industry averages because the diabetes-and-obesity therapeutic focus produces R&D leverage on a single broad patient pool. Third, manufacturing scale: insulin and GLP-1 manufacturing produced at industrial scale at Kalundborg and other Novo Nordisk sites achieves cost-of-goods levels that smaller-volume pharma manufacturers cannot match. Free cash flow reached DKK 100 billion (approximately $14.5 billion) in 2024, with return on invested capital well above 50%. The financial profile supports the substantial Novo Nordisk Foundation philanthropic distributions and the parent Novo Holdings' M&A capacity that funded the 2024 Catalent acquisition.
Novo Nordisk's share price retraced from a September 2023 peak of approximately DKK 1,025 to a 2024-2025 trading range of DKK 600-750, a drawdown of roughly 30-40% from peak that reduced market capitalization from approximately $570 billion at peak to roughly $400-450 billion. The drawdown was driven by three convergent factors. First, the December 2024 CagriSema Phase III readout disappointed investor expectations. CagriSema — a combination of cagrilintide (a long-acting amylin analog) and semaglutide that Novo Nordisk had positioned as a successor obesity medicine targeting greater weight loss than tirzepatide — produced average weight loss of approximately 22.7% over 68 weeks, below the 25%+ that consensus had anticipated and only modestly differentiated from tirzepatide. Second, Eli Lilly's tirzepatide franchise (Mounjaro for diabetes, Zepbound for obesity) gained commercial momentum through 2024 with broader payer coverage and direct-to-consumer pricing initiatives (Lilly Direct, $399 monthly for select Zepbound doses) that pressured Novo Nordisk's market share. Third, US political pressure on GLP-1 pricing intensified with September 2024 Senate hearings and Inflation Reduction Act semaglutide negotiation entering the 2027 implementation cycle. Combined, the drawdown reflected a re-rating of GLP-1 growth and pricing assumptions rather than absolute revenue decline. Underlying revenue continued to grow at 25%+ through 2024.
Novo Nordisk has paid continuously growing dividends since at least the early 2000s, with 2024 annual dividend of DKK 11.40 per share representing total dividend distributions of approximately DKK 50 billion ($7.3 billion). The dividend growth rate has averaged 15-20% annually across the 2020-2024 period as semaglutide revenue accelerated. Share-repurchase programs have run continuously, with 2024 buybacks of approximately DKK 20 billion ($3 billion) reducing share count modestly. Combined return of capital (dividend plus buyback) typically runs at 50-60% of free cash flow, with the remainder funding manufacturing capital expenditure (which has expanded materially through 2022-2024 to support GLP-1 supply) and selective M&A. Capital expenditures have grown from DKK 8 billion in 2020 to over DKK 35 billion in 2024 as the manufacturing footprint expanded across Kalundborg (Denmark), Clayton (North Carolina), Hillerød (Denmark), Tianjin (China), and Chartres (France). The 2024 Novo Holdings Catalent acquisition ($16.5 billion total, with $11 billion of facilities sold to Novo Nordisk) further deployed capital into manufacturing capacity. The Novo Nordisk Foundation receives the majority of distributed dividends as the controlling shareholder, with those dividends in turn funding the Foundation's biomedical research grants — connecting the financial performance of the company to the scientific philanthropy that the Foundation structure was established to support.
Using these figures? Please credit CorpDigest with a link.
CorpDigest. "Novo Nordisk A/S Revenue & Financials." CorpDigest, https://corpdigest.com/company/novo-nordisk/financials.<div style="font-family:system-ui,sans-serif;font-size:14px;line-height:1.5;border:1px solid #e2e8f0;border-radius:8px;padding:12px 16px;max-width:520px"><strong>Novo Nordisk A/S reported $43B in revenue (FY2024).</strong><br>Source: <a href="https://corpdigest.com/company/novo-nordisk/financials" target="_blank" rel="noopener">CorpDigest — Novo Nordisk A/S financials</a></div>